Bladder-sparing therapy for high-risk non-muscle invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at a treatment approach called trimodality therapy (TMT) that aims to save the bladder in people with high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to standard treatments or have had multiple recurrences. It offers an alternative to bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-muscle invasive bladder cancer (NMIBC), including high-grade or widespread types (Ta, Tis, T1).
- You have had at least two recurrences after surgery, or you could not tolerate or did not respond to intravesical therapy (like BCG).
- You have chosen to avoid bladder removal and want to try bladder-sparing therapy (TMT).
- You are 18 years or older.
- Your overall health status is good enough for chemoradiotherapy (your doctor will check blood counts, liver and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
This study follows people with muscle-invasive bladder cancer who choose to keep their bladder (instead of removing it) after receiving chemotherapy, immunotherapy, or an ADC drug. It aims to see how well this approach works and what side effects may occur.
This trial studies a bladder-sparing treatment plan that uses MRI to guide therapy for muscle-invasive bladder cancer. It combines maximal tumor removal, chemotherapy, and radiation to avoid bladder removal.
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
This study tests a combination of chemotherapy, immunotherapy, and radiation to treat muscle-invasive bladder cancer while trying to avoid bladder removal. It compares this approach to a watch-and-wait strategy, and also looks at adding maintenance immunotherapy.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Hear when a new High - Risk NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.